Antibiotics for VRE
Linezolid 600 mg IV or PO every 12 hours is the strongest recommendation for most VRE infections, with treatment duration dependent on infection site and clinical response. 1
Treatment by Infection Site
Bacteremia (Bloodstream Infections)
- First-line: Linezolid 600 mg IV/PO q12h (Strong recommendation, 1C) 1
- Alternative: High-dose daptomycin 8-12 mg/kg IV daily (Weak recommendation, 2C) 1
- Duration: 10-14 days 1
Key mortality data: Meta-analysis showed mortality of 32.8% with linezolid vs 35.7% with daptomycin (RR 1.24, p=0.03), though microbiologic cure rates were comparable at 91% vs 93% 1
Intra-abdominal Infections
- First-line: Linezolid 600 mg IV/PO q12h (Strong recommendation, 1C) 1
- Alternative: Tigecycline 100 mg IV loading dose, then 50 mg IV q12h (Weak recommendation, 2D) 1
- Duration: 5-7 days based on clinical response 1
Uncomplicated Urinary Tract Infections
Multiple oral options available (all Weak recommendations, 2D):
- Fosfomycin: 3 g PO single dose 1
- Nitrofurantoin: 100 mg PO q6h 1
- High-dose ampicillin: 18-30 g IV daily in divided doses 1
- Amoxicillin: 500 mg PO/IV q8h 1
- Duration: 3-7 days 1
Critical caveat: 82% of VRE E. faecalis isolates remain ampicillin-susceptible despite vancomycin resistance 2. High urinary ampicillin concentrations can overcome resistance in UTIs, achieving clinical/microbiological eradication rates of 88.1%/86% even in ampicillin-resistant VRE 1
Complicated Urinary Tract Infections
- First-line: Linezolid 600 mg IV/PO q12h (Strong recommendation, 1C) 1
- Alternative: Daptomycin 6-12 mg/kg IV daily (Weak recommendation, 2D) 1
- Duration: 5-7 days 1
Pneumonia
Critical Clinical Pearls
Avoid common pitfalls:
- Never use tigecycline for bacteremia—low serum levels make it ineffective despite in vitro activity 1
- Daptomycin requires dose escalation for bacteremia: Standard 6 mg/kg is insufficient; use 8-12 mg/kg 1
- β-lactam combinations with daptomycin work best at high daptomycin doses (≥9 mg/kg) and lower MICs (≤2 mg/L) 1
- Don't overlook ampicillin for UTIs: Despite being VRE, most E. faecalis remains ampicillin-susceptible 2
Stewardship concern: Daptomycin is frequently overused (19% of cases) despite 82% ampicillin susceptibility in VRE E. faecalis 2. Always check susceptibilities before defaulting to broad-spectrum agents.
Combination therapy considerations:
- Reserve for severely ill patients, treatment failures, or high daptomycin MIC (3-4 mg/mL) 1
- Daptomycin + β-lactams shows synergy, particularly with ampicillin or ceftaroline 1
- Limited data exists for other combinations (gentamicin, rifampin, linezolid combinations) 1
Endocarditis: Requires cardiac surgery consultation combined with antimicrobial therapy 1